Vir Biotechnology trades near cash value with significant upside potential. The biotech company, which lost revenue when its COVID monoclonal antibody sotrovimab became ineffective, is now positioning itself as a pre-revenue stage firm with pivotal late-stage assets. Lead candidates Tobevibart and Elebsiran target large, underserved markets with potential for high margins and accelerated approval pathways. The Astellas partnership provides crucial funding for oncology development and extends cash runway into 2028, reducing dilution risk. With major catalysts expected between 2026 and 2028, VIR presents asymmetric upside if pivotal trials succeed, supported by strong institutional backing and a solid balance sheet.
Post from MarketNews_en
Log in to interact with content.